Shobha Potluri
Pfizer
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Shobha Potluri.
Nature Genetics | 2014
Laurent C. Francioli; Androniki Menelaou; Sara L. Pulit; Freerk van Dijk; Pier Francesco Palamara; Clara C. Elbers; Pieter B. T. Neerincx; Kai Ye; Victor Guryev; Wigard P. Kloosterman; Patrick Deelen; Abdel Abdellaoui; Elisabeth M. van Leeuwen; Mannis van Oven; Martijn Vermaat; Mingkun Li; Jeroen F. J. Laros; Lennart C. Karssen; Alexandros Kanterakis; Najaf Amin; Jouke-Jan Hottenga; Eric-Wubbo Lameijer; Mathijs Kattenberg; Martijn Dijkstra; Heorhiy Byelas; Jessica van Setten; Barbera D. C. van Schaik; Jan Bot; Isaac J. Nijman; Ivo Renkens
Whole-genome sequencing enables complete characterization of genetic variation, but geographic clustering of rare alleles demands many diverse populations be studied. Here we describe the Genome of the Netherlands (GoNL) Project, in which we sequenced the whole genomes of 250 Dutch parent-offspring families and constructed a haplotype map of 20.4 million single-nucleotide variants and 1.2 million insertions and deletions. The intermediate coverage (∼13×) and trio design enabled extensive characterization of structural variation, including midsize events (30–500 bp) previously poorly catalogued and de novo mutations. We demonstrate that the quality of the haplotypes boosts imputation accuracy in independent samples, especially for lower frequency alleles. Population genetic analyses demonstrate fine-scale structure across the country and support multiple ancient migrations, consistent with historical changes in sea level and flooding. The GoNL Project illustrates how single-population whole-genome sequencing can provide detailed characterization of genetic variation and may guide the design of future population studies.
Nature Genetics | 2014
Jason Flannick; Gudmar Thorleifsson; Nicola L. Beer; Suzanne B.R. Jacobs; Niels Grarup; Noël P. Burtt; Anubha Mahajan; Christian Fuchsberger; Gil Atzmon; Rafn Benediktsson; John Blangero; Bowden Dw; Ivan Brandslund; Julia Brosnan; Frank Burslem; John Chambers; Yoon Shin Cho; Cramer Christensen; Desiree Douglas; Ravindranath Duggirala; Zachary Dymek; Yossi Farjoun; Timothy Fennell; Pierre Fontanillas; Tom Forsén; Stacey Gabriel; Benjamin Glaser; Daniel F. Gudbjartsson; Craig L. Hanis; Torben Hansen
Loss-of-function mutations protective against human disease provide in vivo validation of therapeutic targets, but none have yet been described for type 2 diabetes (T2D). Through sequencing or genotyping of ∼150,000 individuals across 5 ancestry groups, we identified 12 rare protein-truncating variants in SLC30A8, which encodes an islet zinc transporter (ZnT8) and harbors a common variant (p.Trp325Arg) associated with T2D risk and glucose and proinsulin levels. Collectively, carriers of protein-truncating variants had 65% reduced T2D risk (P = 1.7 × 10−6), and non-diabetic Icelandic carriers of a frameshift variant (p.Lys34Serfs*50) demonstrated reduced glucose levels (−0.17 s.d., P = 4.6 × 10−4). The two most common protein-truncating variants (p.Arg138* and p.Lys34Serfs*50) individually associate with T2D protection and encode unstable ZnT8 proteins. Previous functional study of SLC30A8 suggested that reduced zinc transport increases T2D risk, and phenotypic heterogeneity was observed in mouse Slc30a8 knockouts. In contrast, loss-of-function mutations in humans provide strong evidence that SLC30A8 haploinsufficiency protects against T2D, suggesting ZnT8 inhibition as a therapeutic strategy in T2D prevention.
BMC Bioinformatics | 2007
Daniel R. Caffrey; Paul H Dana; Vidhya Mathur; Marco Ocano; Eun-Jong Hong; Yaoyu E Wang; Shyamal Somaroo; Brian E Caffrey; Shobha Potluri; Enoch S. Huang
BackgroundBy virtue of their shared ancestry, homologous sequences are similar in their structure and function. Consequently, multiple sequence alignments are routinely used to identify trends that relate to function. This type of analysis is particularly productive when it is combined with structural and phylogenetic analysis.ResultsHere we describe the release of PFAAT version 2.0, a tool for editing, analyzing, and annotating multiple sequence alignments. Support for multiple annotations is a key component of this release as it provides a framework for most of the new functionalities. The sequence annotations are accessible from the alignment and tree, where they are typically used to label sequences or hyperlink them to related databases. Sequence annotations can be created manually or extracted automatically from UniProt entries. Once a multiple sequence alignment is populated with sequence annotations, sequences can be easily selected and sorted through a sophisticated search dialog. The selected sequences can be further analyzed using statistical methods that explicitly model relationships between the sequence annotations and residue properties. Residue annotations are accessible from the alignment viewer and are typically used to designate binding sites or properties for a particular residue.Residue annotations are also searchable, and allow one to quickly select alignment columns for further sequence analysis, e.g. computing percent identities. Other features include: novel algorithms to compute sequence conservation, mapping conservation scores to a 3D structure in Jmol, displaying secondary structure elements, and sorting sequences by residue composition.ConclusionPFAAT provides a framework whereby end-users can specify knowledge for a protein family in the form of annotation. The annotations can be combined with sophisticated analysis to test hypothesis that relate to sequence, structure and function.
Twin Research and Human Genetics | 2013
Kai Ye; Marian Beekman; Eric-Wubbo Lameijer; Yanju Zhang; Matthijs Moed; Erik B. van den Akker; Joris Deelen; Jeanine J. Houwing-Duistermaat; Dennis Kremer; Seyed Yahya Anvar; Jeroen F. J. Laros; David Jones; Keiran Raine; Ben Blackburne; Shobha Potluri; Quan Long; Victor Guryev; Ruud van der Breggen; Rudi G. J. Westendorp; Peter A. C. 't Hoen; Johan T. den Dunnen; Gert Jan B. van Ommen; Gonneke Willemsen; Steven J. Pitts; David R. Cox; Zemin Ning; Dorret I. Boomsma; P. Eline Slagboom
It has been postulated that aging is the consequence of an accelerated accumulation of somatic DNA mutations and that subsequent errors in the primary structure of proteins ultimately reach levels sufficient to affect organismal functions. The technical limitations of detecting somatic changes and the lack of insight about the minimum level of erroneous proteins to cause an error catastrophe hampered any firm conclusions on these theories. In this study, we sequenced the whole genome of DNA in whole blood of two pairs of monozygotic (MZ) twins, 40 and 100 years old, by two independent next-generation sequencing (NGS) platforms (Illumina and Complete Genomics). Potentially discordant single-base substitutions supported by both platforms were validated extensively by Sanger, Roche 454, and Ion Torrent sequencing. We demonstrate that the genomes of the two twin pairs are germ-line identical between co-twins, and that the genomes of the 100-year-old MZ twins are discerned by eight confirmed somatic single-base substitutions, five of which are within introns. Putative somatic variation between the 40-year-old twins was not confirmed in the validation phase. We conclude from this systematic effort that by using two independent NGS platforms, somatic single nucleotide substitutions can be detected, and that a century of life did not result in a large number of detectable somatic mutations in blood. The low number of somatic variants observed by using two NGS platforms might provide a framework for detecting disease-related somatic variants in phenotypically discordant MZ twins.
Human Molecular Genetics | 2015
Manasi Malik; Joe Chiles; Hualin S Xi; Christopher Medway; James Simpson; Shobha Potluri; Dianna Howard; Ying Liang; Christian M. Paumi; Shubhabrata Mukherjee; Paul K. Crane; Steven G. Younkin; David W. Fardo; Steven Estus
The CD33 single-nucleotide polymorphism (SNP) rs3865444 has been associated with the risk of Alzheimers disease (AD). Rs3865444 is in linkage disequilibrium with rs12459419 which has been associated with efficacy of an acute myeloid leukemia (AML) chemotherapeutic agent based on a CD33 antibody. We seek to evaluate the extent to which CD33 genetics in AD and AML can inform one another and advance human disease therapy. We have previously shown that these SNPs are associated with skipping of CD33 exon 2 in brain mRNA. Here, we report that these CD33 SNPs are associated with exon 2 skipping in leukocytes from AML patients and with a novel CD33 splice variant that retains CD33 intron 1. Each copy of the minor rs12459419T allele decreases prototypic full-length CD33 expression by ∼ 25% and decreases the AD odds ratio by ∼ 0.10. These results suggest that CD33 antagonists may be useful in reducing AD risk. CD33 inhibitors may include humanized CD33 antibodies such as lintuzumab which was safe but ineffective in AML clinical trials. Here, we report that lintuzumab downregulates cell-surface CD33 by 80% in phorbol-ester differentiated U937 cells, at concentrations as low as 10 ng/ml. Overall, we propose a model wherein a modest effect on RNA splicing is sufficient to mediate the CD33 association with AD risk and suggest the potential for an anti-CD33 antibody as an AD-relevant pharmacologic agent.
Cancer Research | 2016
Todd C. Metzger; Hua Long; Shobha Potluri; Thomas Pertel; Samantha L. Bailey-Bucktrout; John C. Lin; Tihui Fu; Padmanee Sharma; James P. Allison; Reid Feldman
ICOS is a T-cell coregulatory receptor that provides a costimulatory signal to T cells during antigen-mediated activation. Antitumor immunity can be improved by ICOS-targeting therapies, but their mechanism of action remains unclear. Here, we define the role of ICOS signaling in antitumor immunity using a blocking, nondepleting antibody against ICOS ligand (ICOS-L). ICOS signaling provided critical support for the effector function of CD4(+) Foxp3(-) T cells during anti-OX40-driven tumor immune responses. By itself, ICOS-L blockade reduced accumulation of intratumoral T regulatory cells (Treg), but it was insufficient to substantially inhibit tumor growth. Furthermore, it did not impede antitumor responses mediated by anti-4-1BB-driven CD8(+) T cells. We found that anti-OX40 efficacy, which is based on Treg depletion and to a large degree on CD4(+) effector T cell (Teff) responses, was impaired with ICOS-L blockade. In contrast, the provision of additional ICOS signaling through direct ICOS-L expression by tumor cells enhanced tumor rejection and survival when administered along with anti-OX40 therapy. Taken together, our results showed that ICOS signaling during antitumor responses acts on both Teff and Treg cells, which have opposing roles in promoting immune activation. Thus, effective therapies targeting the ICOS pathway should seek to promote ICOS signaling specifically in effector CD4(+) T cells by combining ICOS agonism and Treg depletion. Cancer Res; 76(13); 3684-9. ©2016 AACR.
Blood | 2016
Erik B. van den Akker; Steven J. Pitts; Joris Deelen; Matthijs Moed; Shobha Potluri; Jeroen van Rooij; H. Eka D. Suchiman; N. Lakenberg; Wesley J. de Dijcker; André G. Uitterlinden; Robert Kraaij; Albert Hofman; Anton J. M. de Craen; Jeanine J. Houwing-Duistermaat; Gert-Jan B. van Ommen; David R. Cox; Joyce B. J. van Meurs; Marian Beekman; Marcel J. T. Reinders; P. Eline Slagboom
To the editor: Recent large-scale sequencing studies report recurrent somatic mutations in the blood of elderly individuals in genes previously linked to clonal expansion of hematopoietic stem cells.[1][1][⇓][2][⇓][3]-[4][4] Particularly for DNMT3A and TET2 , a steep age-associated increase in
European Journal of Human Genetics | 2017
Laurent C. Francioli; Mircea Cretu-Stancu; Kiran Garimella; Menachem Fromer; Wigard P. Kloosterman; Cisca Wijmenga; Principal Investigator; Morris A. Swertz; Cornelia M. van Duijn; Dorret I. Boomsma; PEline Slagboom; Gert-Jan B. van Ommen; Paul I. W. de Bakker; Freerk van Dijk; Androniki Menelaou; Pieter B. T. Neerincx; Sara L. Pulit; Patrick Deelen; Clara C. Elbers; Pier Francesco Palamara; Itsik Pe'er; Abdel Abdellaoui; Mannis van Oven; Martijn Vermaat; Mingkun Li; Jeroen F. J. Laros; Mark Stoneking; Peter de Knijff; Manfred Kayser; Jan H. Veldink
Germline mutation detection from human DNA sequence data is challenging due to the rarity of such events relative to the intrinsic error rates of sequencing technologies and the uneven coverage across the genome. We developed PhaseByTransmission (PBT) to identify de novo single nucleotide variants and short insertions and deletions (indels) from sequence data collected in parent-offspring trios. We compute the joint probability of the data given the genotype likelihoods in the individual family members, the known familial relationships and a prior probability for the mutation rate. Candidate de novo mutations (DNMs) are reported along with their posterior probability, providing a systematic way to prioritize them for validation. Our tool is integrated in the Genome Analysis Toolkit and can be used together with the ReadBackedPhasing module to infer the parental origin of DNMs based on phase-informative reads. Using simulated data, we show that PBT outperforms existing tools, especially in low coverage data and on the X chromosome. We further show that PBT displays high validation rates on empirical parent-offspring sequencing data for whole-exome data from 104 trios and X-chromosome data from 249 parent-offspring families. Finally, we demonstrate an association between father’s age at conception and the number of DNMs in female offspring’s X chromosome, consistent with previous literature reports.
PLOS ONE | 2015
Marina Sirota; Gonneke Willemsen; Purnima Sundar; Steven J. Pitts; Shobha Potluri; Edi Prifti; Sean Kennedy; S. Dusko Ehrlich; Jacoline Neuteboom; Cornelis Kluft; Karen E. Malone; David R. Cox; Eco J. C. de Geus; Dorret I. Boomsma
Twin and family studies have established the contribution of genetic factors to variation in metabolic, hematologic and immunological parameters. The majority of these studies analyzed single or combined traits into pre-defined syndromes. In the present study, we explore an alternative multivariate approach in which a broad range of metabolic, hematologic, and immunological traits are analyzed simultaneously to determine the resemblance of monozygotic (MZ) twin pairs, twin-spouse pairs and unrelated, non-cohabiting individuals. A total of 517 participants from the Netherlands Twin Register, including 210 MZ twin pairs and 64 twin-spouse pairs, took part in the study. Data were collected on body composition, blood pressure, heart rate, and multiple biomarkers assessed in fasting blood samples, including lipid levels, glucose, insulin, liver enzymes, hematological measurements and cytokine levels. For all 51 measured traits, pair-wise Pearson correlations, correcting for family relatedness, were calculated across all the individuals in the cohort. Hierarchical clustering techniques were applied to group the measured traits into sub-clusters based on similarity. Sub-clusters were observed among metabolic traits and among inflammatory markers. We defined a phenotypic profile as the collection of all the traits measured for a given individual. Average within-pair similarity of phenotypic profiles was determined for the groups of MZ twin pairs, spouse pairs and pairs of unrelated individuals. The average similarity across the full phenotypic profile was higher for MZ twin pairs than for spouse pairs, and lowest for pairs of unrelated individuals. Cohabiting MZ twins were more similar in their phenotypic profile compared to MZ twins who no longer lived together. The correspondence in the phenotypic profile is therefore determined to a large degree by familial, mostly genetic, factors, while household factors contribute to a lesser degree to profile similarity.
mAbs | 2018
Thomas Van Blarcom; Kevin Lindquist; Zea Melton; Wai Ling Cheung; Chris Wagstrom; Dan McDonough; Cendy Valle Oseguera; Sheng Ding; Andrea Rossi; Shobha Potluri; Purnima Sundar; Steven J. Pitts; Marina Sirota; Meri Galindo Casas; Yu Yan; Jeffrey Jones; Zygy Roe-Zurz; Surabhi Srivatsa Srinivasan; Wenwu Zhai; Jaume Pons; Arvind Rajpal; Javier Chaparro-Riggers
ABSTRACT The commercial success of bispecific antibodies generally has been hindered by the complexities associated with generating appropriate molecules for both research scale and large scale manufacturing purposes. Bispecific IgG (BsIgG) based on two antibodies that use an identical common light chain can be combined with a minimal set of Fc mutations to drive heavy chain heterodimerization in order to address these challenges. However, the facile generation of common light chain antibodies with properties similar to traditional monoclonal antibodies has not been demonstrated and they have only been used sparingly. Here, we describe the design of a synthetic human antibody library based on common light chains to generate antibodies with biochemical and biophysical properties that are indistinguishable to traditional therapeutic monoclonal antibodies. We used this library to generate diverse panels of well-behaved, high affinity antibodies toward a variety of epitopes across multiple antigens, including mouse 4-1BB, a therapeutically important T cell costimulatory receptor. Over 200 BsIgG toward 4-1BB were generated using an automated purification method we developed that enables milligram-scale production of BsIgG. This approach allowed us to identify antibodies with a wide range of agonistic activity that are being used to further investigate the therapeutic potential of antibodies targeting one or more epitopes of 4-1BB.